Intellectual Disability (ID) is a clinically heterogeneous condition that affects 2-3% of population worldwide. In recent years, exome sequencing has been a successful strategy for studies of genetic causes of ID, providing a growing list of both candidate and validated ID genes. In this study, exome sequencing was performed on 28 ID patients in 27 patient-parent trios with the aim to identify de novo variants (DNVs) in known and novel ID associated genes. We report the identification of 25 DNVs out of which five were classified as pathogenic or likely pathogenic. Among these, a two base pair deletion was identified in the PUF60 gene, which is one of three genes in the critical region of the 8q24.3 microdeletion syndrome (Verheij syndrome). Our result adds to the growing evidence that PUF60 is responsible for the majority of the symptoms reported for carriers of a microdeletion across this region. We also report variants in several genes previously not associated with ID, including a de novo missense variant in NAA15. We highlight NAA15 as a novel candidate ID gene based on the vital role of NAA15 in the generation and differentiation of neurons in neonatal brain, the fact that the gene is highly intolerant to loss of function and coding variation, and previously reported DNVs in neurodevelopmental disorders.
including inherited recessive variants and dominant de novo variants.
Early genetic diagnosis of ID was limited to large structural abnormalities and targeted tests of known ID genes, which explain 3-6% of cases (Knight et al., 1999) . The introduction of chromosomal microarray analysis (CMA) enables genome-wide investigation with increased resolution, which results in clinical diagnosis of additional 15-20% of ID patients (de Vries et al., 2005; Miller et al., 2010) . The implementation of whole exome sequencing (WES) and whole genome sequencing (WGS) has led to a rapid increase in the discovery of genes with variants associated with ID. WES in trio families has been an especially successful strategy to identify genetic causes of unexplained ID cases, yielding clinically significant findings in 20-30% of patients previously screened by CMA (de Ligt et al., 2012; Miller et al., 2010; Tammimies et al., 2015) . Despite these advances, nearly half of the patients with sporadic ID subjected to genetic testing do not receive a molecular diagnosis. Novel candidate ID genes can be identified by observing variations in the same gene in multiple unrelated ID patients with phenotypic similarity, which underlines the importance of detailed documentation of patient phenotype and the importance of sharing data between clinical laboratories and research initiatives.
In this study, WES was performed in 27 patient-parent trios, where the proband had an ID diagnosis. We report the identification of 25 DNVs, with five variants classified as pathogenic or likely pathogenic according to the American College of Medical Genetics and Genomics (ACMG) guidelines (Richards et al., 2015) . Of the DNVs we identify, we specifically highlight variants in PUF60 and NAA15 as variants providing novel insight into the etiology of ID.
| MATERIALS AND METHODS

| Study design and patients
The participating patients and parents were recruited between 2012 and 2015 in collaboration with the Genetic Diagnostics Unit at Uppsala University Hospital. Ethical approval for WES was received from the Uppsala Ethical Review Board and informed consent was obtained from the parents of all patients. The selection criteria for patients included ID/DD and dysmorphology/congenital malformations while parents had to be healthy with no family history of neurodevelopmental disorders. All patients had previously been screened with CMA (250 K Nsp Array, GenomeWide SNP Array V.6.0, or CytoScan HD [Affymetrix, Santa Clara, CA]) and no pathogenic CNVs had been detected. Genomic DNA was extracted from peripheral blood leucocytes according to standard procedures.
| Exome sequencing and analysis
Exome was enriched using SureSelect v2−5 (Agilent, Santa Clara, CA) and sequenced on SOLiD, Illumina, or IonProton platforms to at least 30x coverage. All reads were mapped to human reference genome Hg19. SOLiD reads were mapped using Bioscope (Life Technologies) and Life Scope (Life Technologies). Illumina reads were mapped using BWA (Li & Durbin, 2009) , and IonProton reads were mapped using the Torrent suit software (Life Technologies).
All programs used for mapping were run using default settings.
Variants were called from SOLiD and Illumina reads using Genome Analysis Toolkit (GATK) and the standard GATK workflow (Broad Institute). Variants were called from IonProton reads using the Torrent suit software (Life Technologies). SNVs were filtered against our in-house database containing previously identified variants as well as dbSNP V.42 (non-flagged). Identified DNVs and inherited variants were validated by Sanger sequencing using standard protocols. Validated variants were interpreted according to the ACMG guidelines. The number of DNVs identified in patient cases and controls in a selected set of previous exome sequencing studies were counted.
3 | RESULTS
| Exome sequencing
Exome sequencing was performed in a total of 27 trio families (28 patients in 27 families) with ID/DD patients. Families were enrolled in the study if results from CMA were negative. A total of 25 heterozygous DNVs were identified within the protein-coding region of 16 patients, with detection of de novo events ranging from 0 to 4 sites per patient. All identified variants were validated by Sanger sequencing.
Out of the 25 validated DNVs we determined five variants in six patients in the genes SMARCA4, FGFR2, SETD5, ASXL3 (two brothers) and PUF60 to be pathogenic or likely pathogenic (Table 1) , following the standards for interpretation of sequencing variants recommended by the ACMG (Richards et al., 2015) . This results in a diagnostic yield of 21% (Table 1) . We also identified a de novo heterozygous nonsynonymous variant of uncertain significance (VUS) in the gene SLC13A5. Although SLC13A5 is a known ID gene, the inheritance pattern in previously reported patients was recessive, and the main symptom of the patients was early infantile epileptic encephalopathy, which is not present in our patient. Several identified DNVs in other genes represent interesting candidates, however, without previous reports and well-established functional studies, these variants were also classified as VUS (Supplemental Table S1 ).
| CADD prediction and previously reported data
In order to predict the deleteriousness of the identified DNVs the combined annotation-dependent depletion (CADD) score was calculated for all variants (Supplemental Table S1 ). CADD scores are a relative measurement of pathogenicity of genetic variants, with higher CADD scores indicating higher pathogenicity (Kircher et al., 2014) . It is reported that pathogenic variants in the OMIM database are significantly enriched for CADD scores over 20 (Shyr et al., 2014 present study had scores >20. Nonsense and loss of function (LoF) variants showed the highest scores (>30), including variants located in SETD5, PUF60, and UTP14C. We also note that nonsynonymous variants in the genes NAA15, KLF16, TAOK1, IRF2BPL, and PARP1 all had CADD scores >20. Several of the nonsynonymous DNVs classified as VUS received a score <10, as did all synonymous DNVs identified.
To find further evidence for pathogenicity of the DNVs that were not scored as pathogenic, we combined data from 13 previous studies in ID and other neurodevelopmental disorders with overlapping genetic causes, including epilepsy and autism spectrum disorder. The combined data includes a total of 5 338 patient trios and 2 181 control trios. Of the 11 genes with nonsense, frameshift, or nonsynonymous DNVs identified in this study, seven genes had DNVs reported in patients in these 13 previous exome studies (Table 2 ). There were between 0 and 6 variants reported in cases for the pathogenic variants identified in this study. The most striking result is that three DNVs have previously been reported in patients with neurodevelopmental disorders in the gene NAA15, while no DNVs have been reported in controls. The DNV identified in NAA15 in our study also had a high CADD score of 24.2. We followed up by searching the DECIPHER database of the gene NAA15, and note that another nonsynonymous DNV in a patient with global developmental delay is reported there (Firth et al., 2009) . In addition, a study has now been published that specifically targeted candidate genes in ID and autism, identifying another 12 likely pathogenic variants in NAA15 (Stessman et al., 2017 ).
An overview of NAA15 with the DNVs identified in patients is shown in Figure 1 .
To further evaluate the genes where DNVs had been identified in patients also in previous studies, we used the Exome Aggregation Consortium (ExAC) browser (Lek et al., 2016) . ExAC reports measures of constraint for all genes and we focused on two relevant metrics reported in ExAC. The measure of Probability of intolerance to loss of function (pLI) 
| DISCUSSION
This WES study identified clinically significant DNV in 6 out of 28 patients with ID, yielding an 21% diagnostic rate, a relatively low yield compared to previous WES studies in trio families with ID patients, which typically ranged from 20-30% (de Ligt et al., 2012; Miller et al., 2010; Tammimies et al., 2015) . Two potential factors could have affected the diagnostic rate. Firstly, the 28 patients were chosen from a larger ID patient cohort without epilepsy. WES results of patients with both ID and epilepsy in the full cohort were previously reported by us with a diagnostic rate of 28% (Halvardson et al., 2016) . The ID patients with epilepsy had generally more severe forehead, low set eyebrows, wide nasal bridge, broad nasal tip, long philtrum, and a thin upper lip (Table 3 ) (Dauber et al., 2013; Deciphering Developmental Disorders, 2017; El Chehadeh et al., 2016; Santos-Simarro et al., 2017) . Moreover, brain and skeletal anomalies also seems to be common among reported cases. These are symptoms that fit well with the phenotype of the patient reported here, a girl with ID, short stature (−3.5 SD), tetrology of fallot, scoliosis, hemivertibrae, and facial features that fits well with the cases described by Dauber and El Chehadeh (Table 3) . However, speech delay seems to be unique for our patient. Thus, our data further support the role for PUF60 as the major contributor to the 8q24.3 deletion phenotype (Dauber et al., 2013) .
Of the DNVs we identified that were not scored as pathogenic,
we searched for evidence of pathogenicity using results from previous exome studies and by using different available tools to score the variants and genes. We find NAA15, encoding the Stessman et al. (2017) .
+, presence of phenotype; −, absence of phenotype; ASD, autism spectrum disorder; DD, developmental delay; ID, intellectual disability; ND, not determined; SGA, small for gestational age. (Deciphering Developmental Disorders, 2015) . This patient has global developmental delay, abnormal facial gestalt and obesity, and carries a 4 bp deletion that results in a frameshift (p.Glu337Argfs*5).
In a recent update of the DECIPHER database (Firth et al., 2009), another de novo variant (nonsense, p.Ser767*) was reported in a patient with global developmental delay, stereotypic behavior, and eczema. Recently, NAA15 was identified as a neurodevelopmental disorder (NDD) risk gene in a study that combined single-molecule molecular inversion probles (smMIPs) with exome sequencing.
Variants in NAA15 were discovered in 13 patients, of which four variants were confirmed to be de novo. The patients shared several key phenotypes including ID (91%), speech delay (83%), Autism Spectrum Disorder (ASD), and diagnosis (63%) (Stessman et al., 2017) . These symptoms fit well with the patient reported here who was small for gestational age, with mild ID, motor, and speech delay including speech dyspraxia ( and was termed mNAT1 (Sugiura et al., 2001) . mNAT1 is expressed at high levels in the neonatal brain in regions of neuronal proliferation and migration, and is dramatically down-regulated during early postnatal development (Sugiura et al., 2001) . The mouse homolog of NAA15, mNAT1, was also shown by in situ hybridization to be highly expressed in areas of cell division and migration and are down-regulated as neurons differentiate, suggesting an important role in the generation and differentiation of neurons (Sugiura, Adams, & Corriveau, 2003) .
Knockdown of Nat1 (NAA15 ortholog) in drosophila caused adult early lethality, erect wings, and impaired locomotor activity (Stessman et al., 2017) . Another knockdown of Nat1 in drosophila was performed with a presumably weaker RNAi line, which led to normal locomotion and morphology, but impaired response in the light-off jump paradigm, as well as habituation deficits (Stessman et al., 2017) . It has been shown that mNAT1 interacts with the protein mARD1 and forms an acetyltransferase complex (Arnesen et al., 2005) . This is noteworthy as the human homolog of mARD1 is NAA10, which together with NAA15 forms the major Nα-terminal acetyltransferase complex (NatA) (Sanchez-Puig & Fersht, 2006) .
The NAA15 missense variant identified in this study is located in the tetraticopeptide-like helical domain, which is a structural motif that mediates protein-protein interactions and the assembly of multiprotein complexes (Figure 1 ). This variant could potentially affect the binding between NAA10 and NAA15. NAA10 is associated with Ogden syndrome, an X-linked neurodevelopment disorder (MIM#300013). Ogden syndrome can be caused by both X-linked dominant inheritance with a milder phenotype, or X-linked recessive inheritance with severe phenotypes, and the syndrome is characterized by postnatal growth failure, delayed psychomotor development, ID, hypotonia, and dysmorphic features (Casey et al., 2015; Popp et al., 2015; Rope et al., 2011) . The phenotype thus shows some shared features with the phenotype reported for patients with NAA15 DNVs.
In summary, our exome sequencing study revealed a limited number of pathogenic variants, but we highlight two variants that we believe contribute new biologically relevant information. We report a small deletion in PUF60 that gives rise to a phenotype similar to Verheij Syndrome, providing further evidence that PUF60 is the major causative gene within the previously reported microdeletion. We also provide multiple lines of evidence suggesting that variants in NAA15 are associated with an ID syndrome. Additional patients and more detailed patient phenotype comparisons will now be required to further refine the role of PUF60 and NAA15 in intellectual disability, and better define the core symptoms associated with causative variants in these genes.
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